The influenza A virus genome consists of eight segments of single-stranded, negative-sense viral RNA, which encode multiple ...

In principle, mRNA vaccines are ideal for health emergencies as they can be quickly mass produced using a template. The problem is that current cell-based template production methods take too long, ...

Cell line development plays a pivotal role in the manufacturing of therapeutic proteins, vaccines and other biologics.

The Financial Times leads on AstraZeneca's decision to scrap plans for a new vaccine manufacturing plant in Liverpool, calling it "a blow to the government's growth agenda". The paper says ...

Our process only requires CO 2 and water as reactants, reducing complexity and cost,” explains Alex Ip, co-founder and CEO of CERT Systems. Similar to the production of “green” hydrogen via water ...

Now he preaches it himself. Pharmaceutical company AstraZeneca on Friday cancelled a planned 450 million-pound ($560 million) investment in a vaccine manufacturing plant in northwest England ...

AstraZeneca has cancelled plans for a £450m vaccine manufacturing plant in Liverpool, blaming a cut in funding from government. The investment, announced last year in the Tories' spring budget ...

The pharmaceutical company, best known for developing the Covid-19 vaccine, said the decision was made after Labour failed to match the previous government’s offer of support. It marks another blow to ...

Facing intense scrutiny from U.S. senators over his potential profit from vaccine lawsuits while serving ... "An amendment to my Ethics Agreement is in process, and it provides that I will divest ...

LONDON (AP) — Pharmaceutical company AstraZeneca on Friday cancelled a planned 450 million-pound ($560 million) investment in a vaccine manufacturing plant in northwest England, blaming the new ...

announced today that it has received approval for a partial amendment to the manufacturing and marketing approval of "KOSTAIVE ® for Intramuscular Injection," a self-amplifying mRNA vaccine for ...

LONDON, Jan 31 (Reuters) - AstraZeneca (AZN.L), opens new tab on Friday scrapped plans to invest 450 million pounds ($558.3 million) in its vaccine manufacturing plant in northern England ...